Close Menu
Search
Reinventing Medicine
Redefining Treatment Paradigms
About Us
Our Company
Leadership
Kymera Cares
Science & Innovation
Our Approach
Pipeline
Resource Library
Careers & Culture
Working at Kymera
Open Positions
Patients
Media
Investors
Patients
Media
Investors
Reinventing Medicine
Redefining Treatment Paradigms
About Us
Our Company
Leadership
Kymera Cares
Science & Innovation
Our Approach
Pipeline
Resource Library
Careers & Culture
Working at Kymera
Open Positions
Search
Back to All Resources
Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune Disease
September 21, 2021
European Protein Degradation Congress
View Presentation
Area of Focus
Immunology
Programs
IRAK4 (KT-474)
Indications
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Development Stage
Pre-clinical Data
Share
You may also be interested in these resources
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
View Resource
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
View Resource
May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
View Resource